Tom Jones joined Ketchum after serving as head of healthcare at Makovsky.
Novartis CEO said pricing environment to worsen; Purdue Pharma offered PBM rebates to get around oxycodone prior authorization; Express Scripts subpoenaed
Here you'll find everything you need to know from MM&M's 50th anniversary issue, including the story behind Viagra, the death of tchotchkes, and much more.
Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health
Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.
GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus
Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand
Excedrin's #DebateHeadache was inspired by complaints the brand noticed during the first presidential debate in September.
Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug
More acquisitions, less IPOs, and more non-traditional stakeholders are among key findings from StartUp Health and Rock Health about the state of digital health funding.
Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market
In the United States, people over 50 are often stereotyped as complacent, set in their ways and extremely loyal to their preferred brands, but a new study released Tuesday by Ketchum found that the opposite is true.
Pfizer to start selling Remicade biosimilar in November; The Medicines Co.'s PCSK9 inhibitor heads to Phase-III trials; J&J's Q3 growth bolstered by autoimmune drugs
Guidemark Health, Bluespire, Bluespire Senior Living, and Ariad Communications will merge under a new entity.
Doctors Without Borders refuses free Pfizer vaccines; Valeant to raise prices of certain drugs; two urologists advocate for overactive bladder drugs
Cleveland Clinic CEO Toby Cosgrove said at the PRWeek Conference that the pharmaceutical industry has a responsibility to manage drug costs without the government stepping in
Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo
Aetna inks value-based deal with Merck in diabetes; new research claims co-pay cards increased drug spend; Xarelto data not affected by device
The partnership allows Sermo to expand the reach of its research initiatives and Everyday Health to scale its targeted advertising on the social platform.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their team.
Valeant is under fire for another price hike; Novartis and Queen Latifah raise awareness about heart failure; critics take aim at co-pay programs
The company hired Christine Cassiano, who is charged with preparing the communications strategy for the drugmaker's experimental cancer therapy.
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.
Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies
The firm will handle communications for scar treatment Mederma and is already managing the product launch of cellulite-treatment product Cellfina, the 10-year anniversary of injectable Radiesse, and introducing a product line.
The company promoted Maryellen Royle to global CEO of Tonic Life Communications and Jon Clark to global CEO of Nitrogen.
73% of derms take industry money; Area 23, Klick Health, and UnitedHealthcare win big at the MM&M Awards; IPG launches healthcare media agency
Three independent agencies — 2e Creative, Klick Health, and StoneArch — each won two gold awards.
Xarelto may cause patients to have more serious bleeding episodes; devicemaker acquires Pfizer's infusion business; Theranos shutters laboratory operations
Roberts reports to Ken Begasse, founder and CEO of Concentric Health Experience.
The FDA to require black-box warnings for hep.-C drugs; AstraZeneca's Brilinta fails to meet study goals; ICER says PD-1s are too pricey
Here, you'll find everything you need to know about MM&M's 2016 Career and Salary Survey, including data on salaries and agency employment trends.
J&J insulin pumps are at risk of hacking; Merrimack CEO leaves and cuts workforce; Japanese scientists wins Nobel
A tracking poll conducted by the Kaiser Family Foundation also found that fewer Americans are seeing prescription drug ads compared to last year.
Mayo Clinic's CEO talks about how a trusted name in healthcare has evolved digitally and centered communications on its newsroom while retaining integrity.
More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
The inside story on a campaign for the ages, as told by the individuals who worked on it.
Did you know that Norman Rockwell was a medical illustrator for Merck?
For some people in the industry ecosystem, the appeal of promo knickknacks endures.
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
Vertex drug challenged by low refill rates; the FDA has issued only 4 warning or untitled letters this year; Horizon settles PBM-rebate suit
With the acquisition of VR developer BioLucid, Sharecare hopes to use empathy to encourage behavior change.
A race has emerged in a new disease space estimated to be worth billions of dollars.
Sharecare acquires virtual-reality developer; Novo Nordisk to cut 1,000 jobs; the FDA approves Medtronic's automated insulin pump
Agency networks such as BBDO, Saatchi & Saatchi, and FCB reported key pharma account wins in August, according to R3.
A new report analyzing gender parity in advertising found that men tend to endorse other men at higher rates than women. Execs share their insights about the issue.
Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry
A study of the social media activity of pharmaceutical firms finds that Lilly is the most active, but Novo Nordisk and Boehringer Ingelheim have better engagement.
Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest
A 2005 study estimated that 3.6 million people do not receive nonemergency medical care because they don't have access to transportation.
The agency denied Pain Therapeutics' and Durect's abuse-deterrent opioid in a complete response letter after warning the drugmakers about how they promoted the drug.
Pfizer drops plans to split into two companies; Merck's Keytruda gains competitive edge in China; Apple may be developing health software
The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.
Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.
Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics
Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus
The organization said it used Facebook to identify participants for a study designed to identify biomarkers associated with Parkinson's disease.
The consultancy includes Double Helix, which was acquired by McCann in 2012.
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Some physicians say they believe they have a responsibility to address the opioid epidemic, but misinformation may hinder them in that pursuit.
WebMD said David Schlanger left the company under mutual agreement, and that Steven Zatz replaced him as CEO.
Ascension worked with several Omnicom agencies on the rebranding push, including FleishmanHillard and Siegel & Gale.
GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck
Alexion launched a new superhero-themed awareness campaign to draw attention to four rare diseases that its products treat.
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
The app's co-founder discusses how it's educating patients and physicians about artificial intelligence and why Cardiogram is different from other heart-rate tracking apps.
The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.
The FDA approves a combination of aspirin and heartburn medication; Teva partners with Intel to develop wearable; New Mexico AG sues BMS and Sanofi
Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness
Sales reps are now more likely to engage with physicians through nonpersonal promotion than in-person visits with doctors at their offices, a ZS report finds.
Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny
A new government investigation found that most but not all prices for generic drugs dispensed by Medicare Part D fell from 2010 to 2015.
For years the social network has been telling advertisers they must pay to magnify their exposure, but most continue to resist.
Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J
The regulator cited inconsistencies with how safety trial data was recorded in a report released ahead of the advisory committee's meeting on Wednesday.
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes
The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.
Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?
One analyst envisions how a first-line approval could set up Keytruda for success in other settings.
New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit
They share their insights, secrets, worries, and everything else in between.
A new study found that orphan drug spending will slow through 2018; senators open inquiry into Mylan; Shires launches branded campaign
The latest TV campaign from Mars features a woman with cerebral palsy joking about her love life.
The regulator charged Celator Pharmaceuticals with promoting an experimental drug as safe and effective even though it has not been approved.
The new SVP and GM of health believes that the Dentsu Aegis deal would provide scale and efficiencies.
BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan
CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.
Pure Communications CEO Andrea Johnston will lead the combined agency.
MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche's cancer drug
Hint: it pays to be an EVP.
"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Five things for pharma marketers to know: Wednesday, October 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy